The Scientific Quest for Lasting Youth: Prospects for Curing Aging — A 2026 Update

New name   B I U S link H1 H2 H3 list 1. x2 x2 page image code pre HTML center hr table note notes desc ▲ ▼	Show page  Syntax
{html} <article> <header> <p class="byline">An in-depth re-examination of João Pedro de Magalhães' 2014 paper, updated with twelve years of breakthroughs in reprogramming, senolytics, epigenetic clocks, AI-driven drug discovery, and the entry of billion-dollar capital into the longevity field.</p> <p class="meta">Originally based on: de Magalhães JP. <em>The Scientific Quest for Lasting Youth: Prospects for Curing Aging.</em> Rejuvenation Research. 2014;17(5):458–467. DOI: <a href="https://journals.sagepub.com/doi/10.1089/rej.2014.1580">10.1089/rej.2014.1580</a></p> </header> <section id="intro"> <h2>Why Revisit a 2014 Paper Now?</h2> <p>In October 2014, the biologist João Pedro de Magalhães — then at the University of Liverpool's Integrative Genomics of Ageing Group — published a perspective piece in <em>Rejuvenation Research</em> that quietly became one of the most-cited surveys of the field's long-term prospects. Its title, "The Scientific Quest for Lasting Youth: Prospects for Curing Aging," framed a question that, at the time, was largely dismissed by mainstream biomedicine: can aging itself, not just its individual diseases, be cured? His answer was deliberately measured. Curing aging, he argued, "is scientifically possible and not even the most challenging enterprise in the biosciences," but he was equally clear that "there is no evidence, however, that we are near to developing the technologies permitting radical life extension."</p> <p>Twelve years on, the question de Magalhães posed has migrated from the fringe of biogerontology into the portfolios of Jeff Bezos, Sam Altman, Peter Thiel, Yuri Milner, and the sovereign wealth funds backing Altos Labs. Cellular reprogramming — barely a research curiosity in 2014 — is now the central thesis of a $3 billion company advised by a Nobel laureate. Epigenetic "clocks" that did not exist when the paper was written are now commercial consumer products. AI-designed drugs targeting aging biology have entered late-stage clinical trials. And yet the core tension de Magalhães identified — between the pace of laboratory discovery and the slowness of clinical translation — remains almost exactly where he left it. This article revisits his arguments in light of what has actually happened between 2014 and 2026.</p> </section> <section id="thesis"> <h2>The Original Thesis, in Brief</h2> <p>De Magalhães structured his 2014 argument around four claims that are worth restating before measuring them against today's evidence:</p> <ol> <li><strong>Curing aging is scientifically possible.</strong> He rejected the position, voiced by researchers like Robin Holliday, that aging is "an impossible task" to understand in its entirety. He pointed to species with negligible senescence — certain fish, turtles, salamanders — and to virtually non-aging organisms like hydra and planaria as existence proofs that complex multicellular life can avoid the deterioration that humans experience.</li> <li><strong>Curing aging is ethically desirable.</strong> He countered the standard objections — overpopulation, inequality, the "naturalness" of death — by noting that Malthusian doom predictions had been wrong for 200 years and that, paradoxically, fertility rates in Japan and Germany were already producing population implosion rather than explosion.</li> <li><strong>Current drug-discovery paradigms will not get us there.</strong> He was skeptical that the small-molecule, single-target approach that dominates pharma R&D could ever deliver radical life extension, even if it produced useful "anti-aging drugs" along the way. He cited the 10–20% clinical approval rate for compounds entering trials as evidence of how poorly we predict biological outcomes.</li> <li><strong>The real breakthroughs needed are computational and genomic.</strong> In his view — and this was the paper's distinctive contribution — the path to radical life extension runs through "unraveling the functioning of the genome" and building "predictive computer models of human biology and disease." He noted that almost half of the roughly 20,000 human protein-coding genes were poorly studied, and that emerging layers of regulation — non-coding RNAs, epigenetics — remained "largely unexplored."</li> </ol> <p>His forecast was explicitly cautious. He quoted NIH Director Francis Collins' 2001 prediction that by 2030 we would have complete models of all human cell types, $1,000 genome sequencing, and a catalog of all aging-related genes — and used it as a benchmark for what exponential progress in genomics might deliver. But he warned that "developing the tools for significantly modifying human biology is crucial to intervening in a complex process like aging," and that the slow clinical translation of gene therapy and regenerative medicine was "a key hurdle for achieving radical life extension in the foreseeable future."</p> </section> <section id="roadmap-revisited"> <h2>The 2014 Roadmap, Revisited Through 2026 Eyes</h2> <h3>1. The "Genomic Revolution" Has Happened — Faster Than Predicted</h3> <p>De Magalhães' Figure 2 plotted the plunging cost of sequencing against Moore's Law and argued that genomics capacity was growing faster than computing power. That trend did not plateau. The $1,000 genome Collins predicted for 2030 was crossed by Illumina in 2014 itself, and by 2023 the cost of a high-quality whole genome had fallen below $200 on some platforms. Long-read sequencing from PacBio and Oxford Nanopore has closed most of the gaps that short-read technology left behind, and the Telomere-to-Telomere (T2T) consortium delivered the first truly complete human genome in 2022 — including the previously unresolvable centromeres and ribosomal DNA arrays that are increasingly understood to be relevant to aging.</p> <p>The other half of de Magalhães' claim — that we needed to actually <em>understand</em> what the genome does — has progressed more slowly but in the direction he predicted. The ENCODE project he cited has been succeeded by ENCODE 4, and large-scale functional genomics efforts like the Human Cell Atlas (launched 2016) now catalog cell-type-specific gene expression across the body. The fraction of "poorly studied" protein-coding genes has fallen meaningfully, though deep functional annotation at the level needed to engineer biology remains incomplete.</p> <h3>2. The Computational Models Are Starting to Exist — and They Are AI</h3> <p>When de Magalhães wrote about "predictive computer models of human biology," he was thinking of whole-cell models like the one published for <em>Mycoplasma genitalium</em> in 2012 — a single-celled organism with 525 genes. Scaling that to a human cell with ~20,000 genes and ~10,000 distinct proteins seemed remote. The breakthrough that has changed this calculus is not more clever differential-equation modeling but deep learning. AlphaFold 2 (2020) and AlphaFold 3 (2024) solved protein structure prediction for nearly every known protein. The ESM family of protein language models from Meta and specialized biology foundation models trained on single-cell transcriptomes can now predict the effects of genetic perturbations with accuracy that was unthinkable in 2014.</p> <p>This is not the same as a working "digital human." But it has shifted the bottleneck de Magalhães identified — the cost and slowness of wet-lab experiments in aging — in a way that aligns with his thesis. Insilico Medicine used its PandaOmics platform to identify TNIK as a fibrosis-and-aging target, design a small molecule (rentosertib, also known as INS018_055), and move from target to Phase I in roughly 30 months — a process that traditionally takes 4–6 years. In July 2026, Insilico announced the start of a Phase III trial for rentosertib in idiopathic pulmonary fibrosis, with the company reporting that six independent proteomic aging clocks indicated biological age reversal in treated patients. If those signals hold in the Phase III readout, it will be the first AI-discovered, AI-designed drug to show a measurable "rejuvenation" signal in a registered clinical trial.</p> <h3>3. Cellular Reprogramming Is the Disruption He Did Not Foresee</h3> <p>Of all the developments since 2014, the one that has most exceeded de Magalhães' framing is partial reprogramming using the Yamanaka factors (Oct4, Sox2, Klf4, c-Myc, often abbreviated OSKM or OSK when c-Myc is omitted for safety). Shinya Yamanaka received the Nobel Prize for this work in 2012, but in 2014 the idea that the same factors could be used <em>in vivo</em> to roll back aspects of aging without fully reprogramming cells into a totipotent state was largely theoretical.</p> <p>That changed in December 2016, when Alejandro Ocampo and colleagues in Juan Carlos Izpisua Belmonte's lab at the Salk Institute published <em>In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming</em> in <em>Cell</em>. By cycling OSKM expression in mice — short pulses that reprogram without pushing cells all the way back to a stem-cell state — they extended lifespan in a mouse model of progeria and improved regeneration in normal mice after pancreatic injury and muscle injury. Crucially, they identified a "point of no return" beyond which reprogramming becomes irreversible and dangerous, establishing that the therapeutic window is narrow but real.</p> <p>In 2020, Yuancheng Lu and colleagues in David Sinclair's lab at Harvard published work in <em>Nature</em> showing that an AAV-delivered three-factor cocktail (OSK, dropping the cancer-linked c-Myc) restored youthful gene expression patterns and — most strikingly — regenerated optic nerve cells in mice, restoring vision in aged animals. Then in January 2023, Sinclair's group published what they called the "ICE" (Inducible Changes to the Epigenome) mouse in <em>Cell</em>. By temporarily inducing DNA double-strand breaks at specific sites in young mice, they caused the epigenome to lose its "information" — the precise pattern of chromatin marks that defines cellular identity — and the mice rapidly displayed many hallmarks of aging. Restoring the factors (via OSK delivery) rolled back those hallmarks. This was the strongest experimental evidence to date for Sinclair's "information theory of aging": that aging is, at its core, a loss of epigenetic information that can in principle be restored.</p> <p>Then came the most striking lifespan result. In March 2024, Cellular Reprogramming published Macip and colleagues' study <em>Gene Therapy-Mediated Partial Reprogramming Extends Lifespan in Aged Mice</em>. The team treated 124-week-old mice (roughly the equivalent of a 75-year-old human) with an AAV9 vector delivering the OSK factors under a doxycycline-inducible promoter, alternating treatment every other week. Treated mice showed a <strong>109% extension of remaining lifespan</strong> — roughly double the remaining lifespan of untreated controls — alongside reduced frailty and reduced epigenetic age in liver and heart tissue. The same group demonstrated that the gene therapy also reduced epigenetic age in cells taken from the scalp of a 65-year-old human. A 2024 paper in <em>Nature Communications</em> by Yücel et al. independently replicated and contextualized the result.</p> <p>None of this is a "cure for aging" in humans. But the trajectory — from theoretical possibility in 2014, to proof-of-concept in progeria mice in 2016, to lifespan extension in normal aged mice in 2024 — is precisely the kind of disruptive technological progress de Magalhães' paper said would be necessary. The October 2025 FDA greenlight of a partial brain reprogramming approach for a first-in-human trial was the regulatory signal that the field is moving from "interesting biology" to "investigational therapy."</p> <h3>4. The Capital Has Arrived — In Sizes de Magalhães Could Not Have Predicted</h3> <p>In 2014, de Magalhães cited Calico (founded by Google in 2013) and Human Longevity Inc. (founded by Craig Venter) as evidence that serious money was finally entering the field. What has happened since dwarfs those bets. In January 2022, Altos Labs emerged from stealth with $3 billion in committed funding — reportedly backed by Jeff Bezos and Yuri Milner — making it the best-funded biotech startup in history at launch. Its founding scientific leadership included Juan Carlos Izpisua Belmonte (Salk), Wolf Reik (Babraham), and Peter Walter (UCSF); Shinya Yamanaka joined as an unpaid senior advisor; Hal Barron left his role as Chief Scientific Officer of GlaxoSmithKline to become CEO. The board included Nobel laureates Jennifer Doudna, Frances Arnold, and David Baltimore.</p> <p>Altos has not been alone. Sam Altman committed $180 million to Retro Biosciences, which has explicitly set itself the goal of adding 10 years to healthy human lifespan. Calico has absorbed more than $2.5 billion in cumulative funding from Alphabet and AbbVie. Hevolution Foundation, backed by Saudi Arabia's royal family, committed $1 billion over a decade to aging research. Loyal, a startup focused on dogs, raised over $125 million to pursue FDA approval of the first drug explicitly approved to extend lifespan in a companion species. The total private capital allocated to longevity-directed biotechs between 2020 and 2025 exceeded $7 billion by most counts — a number that would have seemed fantastical in 2014.</p> <p>The significance of this capital is not just financial. It has changed the talent market. Dozens of the field's most talented postdocs who, in 2014, would have spread across underfunded academic labs are now concentrated in well-resourced institutes with the budgets to do experiments at the scale de Magalhães said was necessary. Whether that produces therapies in time for people alive today is a separate question — but the structural constraint he identified, that "experiments are so time consuming and expensive," has been meaningfully loosened for the first time.</p> <h3>5. The Biomarker Problem He Flagged Has a Solution: Epigenetic Clocks</h3> <p>One of de Magalhães' most pointed practical concerns was that aging research is intrinsically slow because you have to wait for animals (or people) to age to know whether an intervention worked. "Clinical trials are nearly impossible," he wrote, because the endpoint — death — takes decades. He correctly identified this as the field's deepest methodological problem.</p> <p>The partial solution, which did not exist when his paper was published, came in 2013 when Steve Horvath published the first multi-tissue "epigenetic clock" — an algorithm that estimates biological age from DNA methylation patterns at specific CpG sites. The original Horvath Clock has been followed by a cascade of refinements: GrimAge and PhenoAge (second-generation clocks trained on mortality and clinical phenotypes, not just chronological age) and DunedinPACE (a third-generation clock trained on the rate of multi-system physiological decline in a New Zealand birth cohort). These clocks have become the standard surrogate endpoints that aging trials now use to test interventions in months rather than decades.</p> <p>They have limitations, and the field is still arguing about them. Different clocks give different answers on the same sample; most are validated on blood rather than solid tissue; commercial consumer-facing tests vary widely in quality. Horvath — now himself an investigator at Altos Labs — has publicly cautioned that these clocks were designed for epidemiological stratification, not individual clinical decisions, and that organ-specific age estimates derived from cell-free DNA or machine-learning on blood methylation are still "transitioning from proof-of-concept to early validation." But the practical effect has been enormous: it is now possible to run a 12-week human trial of a candidate geroprotector and report a numerical biological-age change. The TAME trial of metformin, the D+Q senolytic trials, and the Insilico rentosertib program all lean on these clocks as their measurable endpoints.</p> <h3>6. Senolytics: The SENS-style "Damage Repair" Approach Is Now in Humans</h3> <p>De Magalhães devoted space to SENS (Strategies for Engineered Negligible Senescence), Aubrey de Grey's then-controversial framework for treating aging as an engineering problem of removing accumulated damage. Many researchers in 2014 dismissed SENS as overoptimistic. One pillar of the SENS strategy — clearing senescent cells that accumulate with age and secrete pro-inflammatory factors — has since moved squarely into mainstream medicine.</p> <p>The 2015 paper by Zhu, Tchkonia, Pirtskhalava, and Kirkland at the Mayo Clinic identified the dasatinib-plus-quercetin (D+Q) combination as a senolytic cocktail that selectively kills senescent cells. In 2019, Hickson and colleagues published the first human proof-of-concept: a pilot trial in patients with diabetic kidney disease showed that a three-day D+Q course reduced senescent cell burden in adipose tissue biopsies and lowered key circulating inflammatory markers. A series of small human trials followed — in idiopathic pulmonary fibrosis, in Alzheimer's disease models, in chronic kidney disease — most showing measurable reductions in senescent cell markers or in clinical surrogates. A 2026 paper by Bian et al. in <em>EBioMedicine</em> reported that D+Q reduced kidney inflammation, senescent cell abundance, and injury while restoring "geroprotective factors" in murine diabetic kidney disease, adding to the translational evidence base.</p> <p>Senolytic development has not been a straight line. Several senolytic biotech startups have shuttered; efficacy signals in humans have been modest and short-lived; the field has had to grapple with whether intermittent dosing (the standard approach, designed to avoid clearing senescent cells that are performing useful tumor-suppressive functions) is actually optimal. But the fact that senolytic human trials exist at all — and that Unity Biotechnology, resTORbio, and others have pushed candidates through Phase 2 — would have been almost inconceivable to a 2014 reader of de Magalhães' paper.</p> <h3>7. Pharmacology: mTOR, NAD+, Taurine, GLP-1s, and the Limits of Single Molecules</h3> <p>De Magalhães was cautious about the near-term prospects for anti-aging drugs, writing that even "if we can develop therapies that mimic CR [caloric restriction] or the longevity effects of genes observed in model organisms, such therapies will not radically extend our life span." The decade since has largely vindicated that caution while also revealing several genuinely promising compounds:</p> <ul> <li><strong>Rapamycin</strong> remains the most robust life-extending drug in mammals, with consistent lifespan extensions of 14–26% in mice across many labs. The Dog Aging Project's TRIAD (Test of Rapamycin in Aging Dogs) trial — rescued by a $7 million grant in February 2025 after a funding crisis — has reported improvements in cardiac function, cognition, and mobility in middle-aged companion dogs, with full lifespan results expected in 2027. A human trial of low-dose rapamycin for age-related outcomes (the RoAD study) is ongoing.</li> <li><strong>NAD+ precursors (NMN, NR)</strong> have been a rollercoaster. After years of preclinical promise, Kane and colleagues in David Sinclair's lab published in 2024 that long-term NMN treatment starting at midlife increased median lifespan by <strong>8.5% in female mice</strong> — but had no significant effect on male mouse lifespan, a sex-specific outcome that itself illustrates the precision de Magalhães warned was lacking. Human NMN trials have shown modest improvements in insulin sensitivity and walking endurance in prediabetic older adults but no lifespan signal.</li> <li><strong>Taurine</strong> entered the conversation in June 2023 when Parminder Singh and a large international team published <em>Taurine deficiency as a driver of aging</em> in <em>Science</em>. Taurine levels decline with age in mice, monkeys, and humans; oral supplementation extended mouse lifespan by 10–12% and improved bone, muscle, immune, and metabolic markers in middle-aged monkeys. However, a June 2025 <em>Nature</em> paper challenged the strength of the human association, finding "limited connection between ageing and taurine levels" in larger human cohorts — a useful corrective on how much aging biology in model systems actually translates.</li> <li><strong>Metformin</strong>, the long-running hope of the TAME (Targeting Aging with Metformin) trial designed by Nir Barzilai at Albert Einstein College of Medicine, has finally enrolled its first cohorts after years of regulatory and funding delays. Whether metformin — a mild AMPK activator with off-target effects on inflammation and IGF-1 signaling — actually moves the needle on multi-system aging outcomes in non-diabetic older adults remains one of the most important open questions in human geroprotection.</li> <li><strong>GLP-1 receptor agonists</strong> (semaglutide, tirzepatide, retatrutide) emerged in 2025–2026 as an unexpected wild card. In June 2026, UC San Diego researchers published early clinical evidence that semaglutide may slow molecular markers of biological aging — likely through inflammation reduction and visceral fat loss rather than direct action on aging pathways. In September 2026, an NIH-supported study reported that GLP-1 treatment late in life extends lifespan in an animal model, mimicking some benefits of caloric restriction. The mechanism is almost certainly not "curing aging" — but if validated, GLP-1s may become the first mass-market drug with measurable geroprotective effects, simply by reducing the chronic inflammatory burden of obesity.</li> </ul> <p>Taken together, these compounds vindicate de Magalhães' skepticism that "the current drug discovery paradigm" would by itself cure aging. The lifespan extensions from any single molecule in mammals remain in the 8–25% range — exactly the "modest" outcome he predicted. But they also suggest that a layered combination of mTOR inhibition + senescent cell clearance + NAD+ restoration + metabolic optimization, refined against epigenetic clock readouts, may produce effects no single drug can deliver alone. The first combination-geroprotector trials are now being designed.</p> <h3>8. The Plateau Question: Are We Already Near the Limits?</h3> <p>The sharpest counterargument to all of this came in October 2024, when a paper in <em>Nature Aging</em> by S. Jay Olshansky and colleagues concluded that radical life extension is unlikely without interventions that target aging itself. The analysis looked at historical life expectancy data and projected that, even under optimistic assumptions about medical progress, female life expectancy at birth in the longest-lived countries would plateau at around 87 years, with maximum individual lifespans unlikely to exceed ~122 years (the age at which Jeanne Calment died in 1997) without directly targeting aging biology.</p> <p>This was, in a sense, exactly what de Magalhães had said in 2014: life expectancy continues to increase "albeit at a modest pace (which some argue may even level off) that does not suggest a trend toward radical life-extension in the foreseeable future." The plateau Olshansky identifies is a ceiling on what incremental medicine can achieve. The implication is that breaking past it requires exactly the kind of interventions de Magalhães' roadmap prescribed: not better statins, but reprogramming, senolytics, gene therapies, and the multi-pronged engineering of biology.</p> <p>So the plateau argument is not actually an argument against curing aging. It is an argument that the 20th-century strategy of fighting diseases one at a time has run its course, and that the next gains must come from a fundamentally different approach. That is the same conclusion de Magalhães reached.</p> </section> <section id="what-unchanged"> <h2>What Has Not Changed Since 2014</h2> <p>For all the progress above, several of de Magalhães' core warnings remain almost uncomfortably prescient:</p> <ul> <li><strong>The translation gap is still the binding constraint.</strong> Gene therapy, stem cell engineering, and synthetic biology have advanced enormously as research tools, but the clinical translation of these technologies for age-related indications remains slow. The 10–20% Phase I-to-approval rate he cited in 2014 has not dramatically improved across biomedicine, and it is arguably worse in aging because the trials are longer, the endpoints more contested, and the regulatory framework (with the FDA historically unwilling to classify aging as a disease) more ambiguous.</li> <li><strong>The causes of aging are still debated.</strong> The 2024 Cell paper "The information theory of aging has not been tested" — by Yang and colleagues, the very group that proposed it — acknowledged that the evidence that epigenetic information loss is a primary driver (rather than a downstream consequence) of aging remains circumstantial. The field now has nine commonly cited "hallmarks of aging" (originally eight, with inflammation added later) versus the looser set of mechanisms de Magalhães listed, but there is no consensus on which are causally primary.</li> <li><strong>The ethics are still unresolved.</strong> De Magalhães' dismissal of overpopulation concerns has aged unevenly. Fertility rates in Japan, Germany, and many other wealthy countries have indeed continued to fall, but global population is still rising and climate and resource constraints are tighter than in 2014. The inequality concern — that life-extension therapies will be available only to the wealthy — has become more acute, not less, as the cost of gene therapy and cell-based treatments routinely reaches six figures per dose.</li> <li><strong>Public ambivalence persists.</strong> The 2013 Pew survey he cited found 56% of Americans would not want treatments to live decades longer. More recent surveys have not shown a dramatic shift. The arrival of actual consumer-facing biological-age tests has not yet produced mass demand for radical life-extension therapies, though interest in "healthspan" — living better, not necessarily longer — has grown sharply.</li> </ul> </section> <section id="where-de-magalhaes-was-wrong"> <h2>Where de Magalhães Was (Slightly) Wrong</h2> <p>His central forecast — that the key to radical life extension lies in "unraveling the genome and the development of computational models" — has held up remarkably well. But two of his subsidiary claims deserve correction:</p> <p>First, he treated regenerative medicine and gene therapy as parallel, somewhat slow-moving tracks. In fact, they have converged with cellular reprogramming in a way he did not anticipate: the most promising delivery vehicles for reprogramming factors are AAV-based gene therapies, and the most promising regenerative applications use reprogrammed patient-derived iPSCs. The fields have merged into what is now called "rejuvenation biotechnology."</p> <p>Second, he underestimated how quickly a few high-profile animal results would unlock private capital at the scale needed to attack the "experiments are slow and expensive" problem. The $3 billion Altos bet, in particular, has compressed decades of academic timelines into a single decade of well-funded private effort. Whether that compression yields clinical results in time for people now in middle age is unknown — but the structural change is real.</p> </section> <section id="bottom-line"> <h2>Bottom Line</h2> <p><strong>If you want to act on this today, here is what is actually available to you, ranked roughly by evidence and accessibility:</strong></p> <ol> <li><strong>Get the boring basics right.</strong> Sleep 7+ hours, regular cardiovascular and resistance exercise, don't smoke, limit alcohol, maintain lean body composition, manage blood pressure and LDL. No longevity biotech in 2026 outperforms the cumulative effect of these on healthspan, and GLP-1 agonists now offer a pharmacological lever for the body-composition piece if diet and exercise alone aren't enough. This is the floor.</li> <li><strong>Get a meaningful biological-age baseline.</strong> A second-generation epigenetic clock (PhenoAge or GrimAge), run on blood, will give you a more useful number than any consumer wellness panel. Treat the result as a stratification tool, not a diagnostic. Repeat at 12-month intervals if you want to track change.</li> <li><strong>Consider rapamycin off-label, with medical supervision.</strong> If you are over 45 with no contraindications, low-dose intermittent rapamycin (typically 3–6 mg once weekly) is the single compound with the strongest mammalian lifespan data and an emerging human safety record. This is not FDA-approved for aging; discuss with a physician who understands the off-label literature. The TRIAD dog results and the human RoAD study are the trials to watch.</li> <li><strong>Track, don't blindly take, NAD+ precursors and metformin.</strong> NMN and NR have human safety data and modest metabolic benefit but weak lifespan evidence; their best use may be in conjunction with biomarker tracking in your 50s and 60s. Metformin is appropriate if you are prediabetic or diabetic; its use as a general geroprotector is unproven and the TAME trial won't read out until late in this decade.</li> <li><strong>For senolytics, wait — unless you have a specific indication.</strong> D+Q cocktails are being used off-label in the longevity community on intermittent schedules, but the human evidence for benefit in healthy adults is thin. If you have an established inflammatory condition, diabetic kidney disease, or IPF, the case for discussing senolytic therapy with a specialist is stronger.</li> <li><strong>Do not wait for reprogramming therapies.</strong> Gene-therapy-based partial reprogramming is the most exciting development since de Magalhães wrote his paper, and the 109% remaining-lifespan extension in aged mice (Macip 2024) and FDA's October 2025 greenlight of a partial brain reprogramming trial are real. But clinical availability for the general population is at least a decade away. Anyone now over 60 should not be planning their life around an reprogramming therapy arriving in time to materially affect them.</li> <li><strong>Engage with the policy debate.</strong> The single biggest determinant of whether the next decade's therapies reach anyone except the very wealthy is whether Medicare, the NHS, and other national systems will reimburse aging-directed interventions. The FDA's ongoing consideration of whether to accept aging-related biomarker endpoints — and the ICD-11 classification work that has begun treating aging as a disease entity — matters more than any individual molecule. Support organizations doing this work (AFAR, the Buck Institute's public policy arm, Hevolution's translational funding) if you want the field to move faster.</li> </ol> <p>Twelve years on from de Magalhães' paper, the headline is that his central thesis was correct and the supporting evidence has grown faster than he predicted. Curing aging is still scientifically possible. It is still not happening on a Kurzweilian timeline. The breakthroughs — reprogramming, senolytics, AI-discovered geroprotectors, billion-dollar capital — are real, but they have moved from "scientifically conceivable" to "early clinical," not from "early clinical" to "widely available." For most readers, the highest-ROI action today is not a futuristic therapy but the deliberate, evidence-based optimization of the tools we already have, while the field builds the next generation.</p> </section> <section id="sources"> <h2>Sources & Further Reading</h2> <ul class="sources"> <li>de Magalhães JP. <em>The Scientific Quest for Lasting Youth: Prospects for Curing Aging.</em> Rejuvenation Research. 2014;17(5):458–467. DOI: <a href="https://journals.sagepub.com/doi/10.1089/rej.2014.1580">10.1089/rej.2014.1580</a> — open-access full text: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4203147">PMC4203147</a></li> <li>Ocampo A, Reddy P, Martinez-Redondo P, et al. <em>In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.</em> Cell. 2016;167(7):1719–1733. DOI: 10.1016/j.cell.2016.11.052</li> <li>Lu Y, Bromberg U, Pollock S, et al. <em>Reprogramming to recover youthful epigenetic information and restore vision.</em> Nature. 2020;588:124–129. PMID: 33268865</li> <li>Yang JH, et al. <em>Loss of epigenetic information as a cause of mammalian aging.</em> Cell. 2023;186(2):305–327</li> <li>Yang JH, et al. <em>The information theory of aging has not been tested.</em> Cell. 2024 — critical reassessment of the ICE mouse data</li> <li>Macip CC, et al. <em>Gene Therapy-Mediated Partial Reprogramming Extends Lifespan in Aged Mice.</em> Cellular Reprogramming. 2024. DOI: 10.1089/cell.2023.0072 — Preprint: <a href="https://www.biorxiv.org/content/10.1101/2023.01.04.522507v1">bioRxiv 2023.01.04.522507</a></li> <li>Yücel AD, et al. <em>The long and winding road of reprogramming-induced rejuvenation.</em> Nature Communications. 2024. DOI: 10.1038/s41467-024-46020-5</li> <li>Singh P, Gollapalli K, Mangiola S, et al. <em>Taurine deficiency as a driver of aging.</em> Science. 2023;380(6649):eabn9257. DOI: 10.1126/science.abn9257</li> <li>"Anti-ageing effects of popular supplement taurine challenged." Nature News. June 5, 2025. DOI: 10.1038/d41586-025-01747-z</li> <li>Kane AE, Chellappa K, et al. <em>Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner.</em> bioRxiv. 2024. DOI: 10.1101/2024.06.21.599604</li> <li>Hickson LTJ, et al. <em>Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.</em> EBioMedicine. 2019;47:446–456. PMID: 31542391</li> <li>Bian X, et al. <em>Senolytics, dasatinib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease.</em> EBioMedicine. 2026</li> <li>Coleman AE, et al. <em>Test of Rapamycin in Aging Dogs (TRIAD).</em> 2025 — Dog Aging Project, <a href="https://dogagingproject.org/triad">dogagingproject.org/triad</a></li> <li>Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. <em>Metformin as a Tool to Target Aging.</em> Cell Metabolism. 2016;23(6):1060–1065. PMC5943638</li> <li>Olshansky SJ, et al. <em>Implausibility of radical life extension in humans in the 21st century.</em> Nature Aging. October 2024 — coverage: <a href="https://hsph.harvard.edu/news/life-expectancy-may-be-reaching-upper-limits-for-now/">Harvard T.H. Chan School of Public Health</a></li> <li>Altos Labs launch announcement (January 2022): <a href="https://www.altoslabs.com">altoslabs.com</a> and C&EN coverage: <a href="https://cen.acs.org/business/start-ups/Altos-Labs-launches-3-billion/100/i3">cen.acs.org</a></li> <li>Insilico Medicine rentosertib (INS018_055) Phase III initiation (July 2026) and proteomic aging clock analysis: <a href="https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr">insilico.com</a> and <a href="https://insilico.com/news/rnt0709261-rentosertib-proteomic-aging-clocks">insilico.com news</a></li> <li>UC San Diego. "Study: Popular GLP-1 Drug May Slow Down Biological Aging." June 2, 2026. <a href="https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging">today.ucsd.edu</a></li> <li>NIH. "GLP-1 treatment late in life extends lifespan in animal model." September 2, 2026. <a href="https://www.nih.gov/news-events/news-releases/glp-1-treatment-late-life-extends-lifespan-animal-model">nih.gov</a></li> <li>Horvath S. Original multi-tissue epigenetic clock. Genome Biology. 2013. See also: <em>Epigenetic Clocks: Beyond Biological Age</em>. Aging and Disease. 2024. DOI: 10.14336/AD.2024.1495</li> <li>Lifespan.io coverage of partial reprogramming and reprogramming senescent cells: <a href="https://lifespan.io/reprogramming-senescent-cells-extends-lifespan-in-mice">lifespan.io</a></li> <li>Eric Topol, "Steve Horvath: Our Epigenetic Age Clocks," Ground Truths (Substack)</li> </ul> </section> <footer> <p class="disclosure"><strong>Disclosure:</strong> This article is for informational purposes and does not constitute medical advice. Off-label uses of rapamycin, metformin, NAD+ precursors, and senolytic combinations should be discussed with a qualified physician. The author has no financial interest in any company mentioned.</p> <p class="published">Published November 2026. Built on de Magalhães (2014), Rejuvenation Research 17(5):458–467.</p> </footer> </article> {/html}
Password  Summary of changes

 📜 ⏱️ ⬆️